14.01.2016 • NewsDede WillamsCatalentRoche

Catalent and Roche Link on SMARTag

Redwood Bioscience, a subsidiary of Catalent, a US-based global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has entered a research collaboration with Switzerland’s Roche to develop next-generation molecules coupling different therapeutic modalities with the help of Catalent's proprietary protein-modification technology SMARTag.

Catalent said the use of use of SMARTag, combined with the highly stable hydrazino-Pictet-Spengler conjugation platform, will permit evaluation of alternative sites of drug conjugation to facilitate development of molecules optimized for efficacy, safety and stability.

As part of the deal, Roche will pay Catalent an upfront fee of $1 million and provide additional research funding during the initial phase of the collaboration. In return, the Swiss drugmaker will gain non-exclusive access to the platform and will have an option to take commercial licenses to develop molecules directed to a defined number of targets.

The US company also could receive up to $618 million in development and commercial milestones, plus royalties on net sales of products, if Roche pursues commercial licenses and all options are exercised.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.